

REMARKS

Claims 1-7, 9-15, 17, 19 and 20 are pending in this application. Claims 1-7 have been allowed.

Claims 9, 10, 12-15, 17, 19 and 20 were rejected under 35 U.S.C. § 112, first paragraph for the specification allegedly not being enabling for a drug delivery device comprising or a method for delivering a “prophylactic agent”. Applicants respectfully disagree with the Examiners assertion. However, in an effort to expedite prosecution, claims 9, 10, 13 and 19 have been amended to delete the term “prophylactic,” thereby obviating the rejection.

No new matter has been introduced by this amendment and this response raises no new issues.

As such, it is respectfully submitted that claims 9, 10, 12-15, 17, 19 and 20 are allowable.

Accordingly, in view of the above amendments and remarks, Applicants respectfully submit that this application should be allowed and the case passed to issue. If there are any questions regarding this Amendment or the application in general, a telephone call to the undersigned would be appreciated to expedite the prosecution of the application.

To the extent necessary, a petition for an extension of time under 37 C.F.R. 1.136 is hereby made. Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 500417 and please credit any excess fees to such deposit account.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP

Aamer S. Ahmed
Registration No. 58,958

600 13th Street, N.W.
Washington, DC 20005-3096
Phone: 202.756.8000 ASA:MWE
Facsimile: 202.756.8087
Date: September 5, 2008

**Please recognize our Customer No. 20277
as our correspondence address.**